BRCA2 and breast carcinoma: A large prospective cohort study published in 2020, including 2272 BRCA1 and 1605 BRCA2 pathogenic variant carriers, did not observe a protective effect of RRBSO regarding breast cancer in BRCA1 mutation carriers.